ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

NCT05062317 PHASE2 RECRUITING

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	PHASE2
Status	RECRUITING
Enrolment	120
Start date	Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Feb 28 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Liver Metastases

Interventions

• Leucovorin
• 5-FLUOROURACIL
• Oxaliplatin
• Irinotecan
• Capecitabine
• Bevacizumab

Countries

United States